Labeling For Optimer's Dificid Includes Data On Ability To Sustain Cure Post-Treatment
This article was originally published in The Pink Sheet Daily
Executive SummaryFDA approves the macrolide antibacterial for treatment of Clostridium difficile-associated diarrhea.
You may also be interested in...
The antibiotic company announced it is reviewing strategic options and that CEO Pedro Lichtinger has been replaced by Chairman Henry McKinnell. Hospital-based companies looking to beef up their portfolios with a commercial asset could drive a competitive process.
Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.
The GAIN Act is intended to spur development of new antibiotics, but incentives like extended market exclusivity and priority review, while important benefits, may not be enough to get investors off the sidelines.